Arbutus Biopharma Corporation (NASDAQ: ABUS), the biopharmaceutical company known for its focus on developing treatments for chronic Hepatitis B virus (HBV) infection, recently received a noteworthy boost in its stock price target. JMP Securities raised its price objective from $4.00 to $5.00,
We haven’t stepped that deep into the 21st century, but we have already witnessed how a microscopic organism like a virus can wreak havoc. They evolve to become more resistant to our usual remedies so we have to escape them in a biological race on an atomic level. Consequently, scientists have come
The bioprocessing sector, a critical component within the Life Sciences industry, continually faces hurdles in bringing innovative technologies from development to market. BioProcess360 Partners has introduced a novel investment fund aimed at bridging this gap. By providing both capital and
Rentschler Biopharma, a fifth-generation, family-owned German biopharmaceutical company, has made tremendous strides in the field of advanced therapies. With its roots tracing back over 150 years, Rentschler has carved out a unique position in the biotechnology landscape, emphasizing innovation,
Sutro Biopharma, Inc., a clinical-stage oncology company, has garnered significant attention from the investment community. Institutional investors like Susquehanna Fundamental Investments LLC recently bolstered their holdings by acquiring 126,459 shares valued at approximately $714,000 during the
The global pharmaceutical industry is undergoing a transformative phase, driven by rapid advancements in technology, increasing demand for healthcare solutions, and strategic expansions by leading companies. Esteve Pharmaceuticals, a major player in the sector, is making headlines with its
Pancreatic cancer is a complex and aggressive disease that remains one of the deadliest forms of cancer. Its market, valued at approximately USD 1.6 billion in 2020 across the 7MM regions (the United States, the EU-4 [Italy, Spain, France, and Germany], the United Kingdom, and Japan), is poised for
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, has reached a pivotal milestone by dosing its first patient in the U.S. for the NEXICART-2 clinical trial. This significant achievement aims to treat relapsed/refractory AL Amyloidosis using CAR-T cell therapy, known as NXC-201.
The recent breakthrough in CAR T-cell manufacturing is nothing short of revolutionary. Researchers from the Critical Analytics for Manufacturing Personalized-Medicine (CAMP) Interdisciplinary Research Group (IRG) at the Singapore-MIT Alliance for Research and Technology (SMART), in collaboration
The healthcare system's history of unethical practices and ongoing issues has fostered a deep mistrust among minority communities. This mistrust affects everything from routine healthcare appointments to participation in clinical trials. Despite significant efforts to increase diversity,
